SPRC ▼ -4.8% - SciSparc Ltd. $SPRC - SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies SciSparc's stock fell 4.8% despite the company's announcement that its subsidiary NeuroThera Labs is pursuing FDA Orphan Drug Designation for a Tourette syndrome treatment and has hired government affairs firm RK Strategies to support the effort. The decline suggests investors may be discounting the regulatory pathway or questioning the commercial potential of the program at this early stage. 02-SEP-2026 08:17 AM ET